Methods and compositions for preventing adhesion
This invention provides methods and compositions for preventing post-surgical adhesion formation based on use of an interleukin-16 (IL-16) antagonist, including an IL-16 antagonist peptide and/or an IL-16 antagonist antibody.
1. A method, comprising administering an IL-16 antagonist to a mammalian subject undergoing surgery to effect at least a reduction in surgery induced adhesion in said subject, wherein said IL-16 antagonist is an anti-IL-16 neutralizing antibody or an antigen-binding fragment thereof, said antibody binds to a peptide fragment of native IL-16 of said subject, and said peptide fragment is of a length of 4-16 amino acids and comprises a RR or KR motif in the C-terminal region of said native IL-16, and wherein said IL-16 antagonist is administered to the subject before, during or not more than 5 days after the surgery.
2. The method of claim 1 , wherein said anti-IL-16 antibody is a polyclonal antibody or a monoclonal antibody.
3. The method of claim 1 , wherein said anti-IL-16 antibody is a human or humanized antibody.
4. The method of claim 1 , where said peptide fragment comprises a sequence selected from the group consisting of: RRKS (SEQ ID NO: 3), VIRR (SEQ ID NO: 9), IRRK (SEQ ID NO: 12), RRKSLQ (SEQ ID NO: 16), RRKSLQSK (SEQ ID NO: 23), and RRKSLQSKETTAAGDS (SEQ ID NO: 32).
5. The method of claim 1 , wherein said IL-16 antagonist is administered in combination with another adhesion-preventive agent or a barrier material.
6. The method of claim 5 , wherein said IL-16 antagonist has been incorporated into or on said barrier material prior to administration.
7. The method of claim 1 , wherein the administration is performed at least during the surgery.
8. The method of claim 1 , wherein the mammalian subject is human.
9. The method of claim 1 , wherein the administration is performed during and after the surgery.